Home  |  Contact

UniProtKB/Swiss-Prot Q9UBP0: Variant p.Ile406Arg

Spastin
Gene: SPAST
Variant information

Variant position:  406
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Isoleucine (I) to Arginine (R) at position 406 (I406R, p.Ile406Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (I) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In SPG4.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  406
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  616
The length of the canonical sequence.

Location on the sequence:   NGKTMLAKAVAAESNATFFN  I SAASLTSKYVGEGEKLVRAL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Mouse                         NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Rat                           NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Pig                           NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Bovine                        NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Chicken                       NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Xenopus laevis                NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Xenopus tropicalis            NGKTMLAKAVAAESNATFFNISAASLTSKYVGEGEKLVRAL

Zebrafish                     NGKTMLAKAVAMESNATFFNISAATLTSKYVGEGEKLVRAL

Caenorhabditis elegans        NGKTLLAKAVAGESKQMFFNISASSLTSKWVGDSEKTIRGL

Drosophila                    NGKTLLARAVATECSATFLNISAASLTSKYVGDGEKLVRAL

Slime mold                    NGKTMIAKAVAYESKVTFFSISSSSLTSKYVGDGEKLVRAL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 616 Spastin
Topological domain 78 – 616 Cytoplasmic
Region 228 – 616 Sufficient for microtubule severing
Mutagenesis 388 – 388 K -> A. Abrogates ATPase activity and abolishes microtubule severing.
Mutagenesis 415 – 415 Y -> A. Abrogates binding to the tail of alpha-tubulin and beta-3-tubulin, impairs ATPase activity and abolishes microtubule severing.
Beta strand 402 – 407


Literature citations

Novel and recurrent spastin mutations in a large series of SPG4 Italian families.
Nanetti L.; Baratta S.; Panzeri M.; Tomasello C.; Lovati C.; Azzollini J.; Gellera C.; Di Bella D.; Taroni F.; Mariotti C.;
Neurosci. Lett. 528:42-45(2012)
Cited for: VARIANTS SPG4 THR-95; 112-GLU--VAL-616 DEL; 135-GLU--VAL-616 DEL; LEU-399; ARG-406; THR-409; VAL-426; 431-ARG--VAL-616 DEL; CYS-460; TRP-503; ARG-559 AND 562-ARG--VAL-616 DEL;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.